Heidelberg, Germany, April 8, 2021 -- Affimed N.V. (Nasdaq: AFMD), a 
clinical-stage immuno-oncology company committed to giving patients back 
their innate ability to fight cancer, announced today that it will 
release full year 2020 results and corporate update on Thursday, April 
15, 2021. The Company will host a conference call at 8:30 a.m. Eastern 
Daylight Time. 
 
   The conference call will be available via phone and webcast. To access 
the call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 
928338 for international callers, and reference conference ID 4271307 
approximately 15 minutes prior to the call. 
 
   To access the live audio webcast of the conference call please visit the 
"Investors" section of the company's website at 
https://www.globenewswire.com/Tracker?data=XTsxj1F5YwvjSkHxe0nDC2Gqb0cr8F8GrKD2y9-RlLAz1FuUu97G9m0oYgAZ9oaTm6aexW7ERBzslwWrA6XISLKVEurNy1JmWzOhvdl50GRdJOGzU6xgx2D4NHbI0Ol91Z9DkIplj6AAtg6t0KR2QPfvOXG5K7LBlmfFpUFIkYU= 
https://www.affimed.com/investors/webcasts_cp/. A replay of the call 
will be archived on the Affimed website for 30 days after the call. 
 
   About Affimed N.V. 
 
   Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company 
committed to give patients back their innate ability to fight cancer by 
actualizing the untapped potential of the innate immune system. The 
company's proprietary ROCK(R) platform enables a tumor-targeted approach 
to recognize and kill a range of hematologic and solid tumors, enabling 
a broad pipeline of wholly-owned and partnered single agent and 
combination therapy programs. The ROCK(R) platform predictably generates 
customized innate cell engager (ICE(R)) molecules, which use patients' 
immune cells to destroy tumor cells. This innovative approach enabled 
Affimed to become the first company with a clinical-stage ICE(R). 
Headquartered in Heidelberg, Germany, with offices in New York, NY, 
Affimed is led by an experienced team of biotechnology and 
pharmaceutical leaders united by a bold vision to stop cancer from ever 
derailing patients' lives. For more about the company's people, pipeline 
and partners, please visit: 
https://www.globenewswire.com/Tracker?data=p-Z-E1BtgOS1vCiZYBcWfVg6x6G8XaHbMhoRhuwziV5V9mBuDsFfSX7dE13O7tTl0NCorjr-W5dqs2B74s8PEA== 
www.affimed.com. 
 
   Investor Relations Contact 
 
   Alex Fudukidis 
 
   Head of Investor Relations 
 
   E-Mail: 
https://www.globenewswire.com/Tracker?data=DYem8437D22U68ZIZp00yU2uUoB28Gisk3qRVdiIiX_xiuA6yg22WEXVHZbeUjE0WSImkp7dgIXOSlaz5TPTVznboDsMW5PK3oVzhbElZFo= 
a.fudukidis@affimed.com 
 
   Tel: +1 (917) 436-8102

(END) Dow Jones Newswires

April 08, 2021 06:30 ET (10:30 GMT)